Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2023 to Q4 2025

Type / Class
Equity / Common Stock, $0.001 par value per share
Symbol
ELVN on Nasdaq
Shares outstanding
59,746,870
Price per share
$15.40
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
59,389,507
Total reported value
$1,215,687,864
% of total 13F portfolios
0%
Share change
-50,817
Value change
-$296,038
Number of holders
132
Price from insider filings
$15.40
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ORBIMED ADVISORS LLC 13% $140,468,212 7,918,163 ORBIMED ADVISORS LLC 16 Jun 2025
FMR LLC 13% $161,103,383 7,870,219 FMR LLC 30 Sep 2025
Commodore Capital LP 9.9% $135,215,385 6,022,957 Commodore Capital LP 30 Jun 2025
Fairmount Funds Management LLC 6.3% -4.3% $83,321,918 +$11,419,103 3,711,444 +16% Fairmount Funds Management LLC 30 Jun 2025
Venrock Healthcare Capital Partners III, L.P. 5.4% $66,042,996 3,226,331 Venrock Healthcare Capital Partners III, L.P. 30 Sep 2025
BlackRock, Inc. 5.1% $59,005,266 2,941,395 BlackRock, Inc. 30 Jun 2025
Polar Capital Holdings Plc 5.2% +5.6% $56,952,978 +$3,304,932 2,536,881 +6.2% Polar Capital Holdings Plc 30 Jun 2025

As of 30 Sep 2025, 132 institutional investors reported holding 59,389,507 shares of Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN). This represents 99% of the company’s total 59,746,870 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN) together control 89% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
ORBIMED ADVISORS LLC 13% 7,959,538 0% 3.9% $162,931,743
FMR LLC 12% 7,129,196 -5.7% 0.01% $145,934,642
Commodore Capital LP 7.9% 4,692,809 0% 4.7% $96,061,800
Fairmount Funds Management LLC 6.2% 3,711,444 0% 6.8% $75,973,259
BlackRock, Inc. 5.9% 3,518,524 +19% 0% $72,024,186
VR ADVISER, LLC 5.4% 3,226,331 -20% 3.7% $66,042,996
Polar Capital Holdings Plc 5.2% 3,095,007 +1.5% 0.31% $63,354,793
VANGUARD GROUP INC 4.3% 2,553,014 +5.9% 0% $52,260,198
JANUS HENDERSON GROUP PLC 3% 1,793,583 +4.5% 0.02% $36,696,708
NOVO HOLDINGS A/S 2.4% 1,426,260 +32% 1.9% $29,195,542
Pictet Asset Management Holding SA 2.3% 1,398,087 +45% 0.03% $28,618,841
Blackstone Inc. 2.2% 1,320,592 0% 0.12% $27,032,518
Capital Research Global Investors 2.2% 1,315,465 0% 0.01% $26,927,569
CITADEL ADVISORS LLC 1.9% 1,160,503 -21% 0.02% $23,755,496
Vestal Point Capital, LP 1.9% 1,160,000 +364% 1.1% $23,745,200
GEODE CAPITAL MANAGEMENT, LLC 1.8% 1,085,013 +23% 0% $22,213,256
Point72 Asset Management, L.P. 1.7% 1,040,410 -23% 0.05% $21,297,200
STATE STREET CORP 1.6% 965,137 +18% 0% $19,756,354
Duquesne Family Office LLC 1.6% 947,405 +105% 0.49% $19,393,000
First Turn Management, LLC 1.3% 783,411 +54% 2.4% $16,036,423
5AM Venture Management, LLC 1.3% 772,477 0% 5.8% $15,812,604
Rock Springs Capital Management LP 1.1% 686,107 -2.2% 0.82% $14,044,610
Candriam S.C.A. 1% 609,352 +46% 0.07% $12,473,435
FRANKLIN RESOURCES INC 0.72% 430,240 0% 0% $8,807,012
Affinity Asset Advisors, LLC 0.67% 400,000 0% 0.76% $8,188,000

Institutional Holders of Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 15,152 $233,202 -$961,731 $15.40 6
2025 Q3 59,389,507 $1,215,687,864 -$296,038 $20.47 132
2025 Q2 59,434,902 $1,192,251,085 +$192,194,924 $20.06 123
2025 Q1 49,886,849 $983,923,667 +$4,352,699 $19.68 118
2024 Q4 49,624,914 $1,116,597,658 +$24,828,957 $22.50 111
2024 Q3 47,688,348 $1,218,010,157 -$20,810,259 $25.54 100
2024 Q2 48,318,843 $1,129,194,355 +$91,652,714 $23.37 91
2024 Q1 44,456,336 $780,753,492 +$95,045,035 $17.59 72
2023 Q4 39,000,634 $539,791,932 -$652,659 $13.84 61
2023 Q3 39,076,502 $533,779,750 -$2,178,662 $13.66 60
2023 Q2 39,092,843 $797,915,923 +$112,876,379 $20.41 61
2023 Q1 33,557,749 $734,910,999 +$734,911,000 $21.90 44